Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CHIEF TECH OP OFFICER

CFO AND SECRETARY

CHIEF PEOPLE & COMM. OFFICER

PRESIDENT AND COO

CHIEF MEDICAL OFFICER

CHIEF PORT. STRAT & ALNCE OFCR

Chief Business Officer

Chief Commercial Officer

Chief Port. Strat & Alnce Ofcr

Pres. Rsrch & Cf. Sctific Ofcr

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sutro Biopharma, Inc. operates as a clinical-stage oncology company.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-01	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF TECH OP OFFICER
2024-05-01	Premium	acquired	Premium	Premium	Premium	CHIEF TECH OP OFFICER
2024-04-11	Premium	acquired	Premium	Premium	Premium	CHIEF TECH OP OFFICER
2024-04-11	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF TECH OP OFFICER
2024-03-05	Premium	sold (taxes)	Premium	Premium	Premium	CFO AND SECRETARY
2024-03-05	Premium	acquired	Premium	Premium	Premium	CFO AND SECRETARY
2024-03-05	Premium	acquired	Premium	Premium	Premium	CHIEF PEOPLE & COMM. OFFICER
2024-03-05	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF PEOPLE & COMM. OFFICER
2024-03-05	Premium	acquired	Premium	Premium	Premium	CEO
2024-03-05	Premium	sold (taxes)	Premium	Premium	Premium	CEO
2024-03-04	Premium	sold (taxes)	Premium	Premium	Premium	CEO
2024-03-04	Premium	acquired	Premium	Premium	Premium	PRESIDENT AND COO
2024-03-04	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF PEOPLE & COMM. OFFICER
2024-03-04	Premium	acquired	Premium	Premium	Premium	CEO
2024-03-04	Premium	acquired	Premium	Premium	Premium	CHIEF PEOPLE & COMM. OFFICER
2024-03-04	Premium	sold (taxes)	Premium	Premium	Premium	CFO AND SECRETARY
2024-03-04	Premium	acquired	Premium	Premium	Premium	CFO AND SECRETARY
2024-03-04	Premium	sold (taxes)	Premium	Premium	Premium	PRESIDENT AND COO
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	CFO AND SECRETARY
2024-03-01	Premium	acquired	Premium	Premium	Premium	CHIEF PEOPLE & COMM. OFFICER
2024-03-01	Premium	acquired	Premium	Premium	Premium	CFO AND SECRETARY
2024-03-01	Premium	acquired	Premium	Premium	Premium	CEO
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF PEOPLE & COMM. OFFICER
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF TECH OP OFFICER
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	PRESIDENT AND COO

STRO - Sutro Biopharma Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for STRO